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Translational relevance: 39 
 40 
Virotherapies are emerging as clinically important anticancer agents, demonstrating synergy with immune 41 
checkpoint inhibitors in several recent, high profile studies. Since these agents have not evolved to be in-42 
trinsically tumour selective, therapeutic index could be further enhanced by a thorough redesign of the virus 43 
capsid to improve tumour selectivity following intravascular delivery. To this end, we have systematically 44 
refined the adenovirus serotype 5 (Ad5) capsid to genetically preclude uptake via all known native cellular 45 
entry pathways, to generate a basal and more biocompatible vector, Ad5NULL. To empower this vector with 46 
tumour selectivity, we further engineered the Ad5NULL capsid to present a high-affinity αvβ6 integrin-binding 47 
oligopeptide, A20. The resultant virotherapy, Ad5NULL-A20 demonstrates exquisite tumour-selectivity both in 48 
vitro and in vivo, with basal “off-target” uptake. Ad5NULL-A20 thus represents a powerful platform for target-49 
ed in situ over-expression of immunomodulatory modalities for future translational applications. 50 
 51 
Abbreviations: 52 
A20, a 20-amino acid peptide NAVPNLRGDLQVLAQKVART 53 
Ad5, adenovirus serotype 5 54 
CAR, coxsackie and adenovirus receptor 55 
EOC, epithelial ovarian cancer 56 
FMDV, foot-and-mouth disease virus 57 
FX, coagulation factor 10 58 
OAS, ovarian ascites 59 
 60 
61 
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ABSTRACT 62 
 63 
Purpose:  64 
Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors 65 
for manipulability and tolerance of transgenes. Poor tumour-selectivity, off-target 66 
sequestration and immune inactivation hamper clinical efficacy. We sought to completely 67 
redesign Ad5 into a refined, tumour selective virotherapy targeted to αvβ6 integrin, which is 68 
expressed in a range of aggressively transformed epithelial cancers but non-detectable in 69 
healthy tissues. 70 
Experimental Design:  71 
Ad5NULL-A20 harbours mutations in each major capsid protein to preclude uptake via all 72 
native pathways. Tumour-tropism via αvβ6-targeting was achieved by genetic insertion of 73 
A20 peptide (NAVPNLRGDLQVLAQKVART) within the fiber knob protein. The vector’s 74 
selectivity in vitro and in vivo was assessed. 75 
Results:  76 
The tropism-ablating triple mutation completely blocked all native cell entry pathways of 77 
Ad5NULL-A20 via coxsackie and adenovirus receptor (CAR), αvβ3/5 integrins and coagulation 78 
factor 10 (FX). Ad5NULL-A20 efficiently and selectively transduced αvβ6+ cell lines and 79 
primary clinical ascites-derived EOC ex vivo, including in the presence of pre-existing anti-80 
Ad5 immunity. In vivo biodistribution of Ad5NULL-A20 following systemic delivery in non-81 
tumour-bearing mice was significantly reduced in all off-target organs, including a 82 
remarkable 107-fold reduced genome accumulation in the liver compared to Ad5. Tumour 83 
uptake, transgene expression and efficacy were confirmed in a peritoneal SKOV3 xenograft 84 
model of human EOC, where oncolytic Ad5NULL-A20-treated animals demonstrated 85 
significantly improved survival compared to those treated with oncolytic Ad5. 86 
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Conclusions:  87 
Oncolytic Ad5NULL-A20 virotherapies represent an excellent vector for local and systemic 88 
targeting of αvβ6-over-expressing cancers, and exciting platforms for tumour selective over-89 
expression of therapeutic anti-cancer modalities, including immune checkpoint inhibitors. 90 
  91 
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INTRODUCTION 92 
Ovarian cancer remains the deadliest gynaecological cancer with global 5-year 93 
survival rates below 50% (1). The early stages of the disease are commonly asymptomatic, 94 
with the result that most patients have advanced, incurable disease, at presentation. Ovarian 95 
cancer metastasises with large volumes of malignant, intraperitoneal ovarian ascites (OAS) 96 
providing a pro-tumourigenic microenvironment (2). Chemo-resistance rapidly develops 97 
during treatment, requiring alternative regimens. Epithelial ovarian cancer (EOC) is the most 98 
common (90%) ovarian cancer type (3). A third of EOC patients have cells expressing an 99 
epithelial cancer-specific marker, αvβ6 integrin (4). Upregulation of αvβ6 expression in 100 
cancer has been linked to aggressive transformation, metastasis and poor prognosis (5-8). 101 
αvβ6 is absent in healthy epithelium (5, 9) but widely over-expressed in plethora of cancers, 102 
including ovarian, lung, skin, oesophageal, cervical, and head and neck cancer (4), thus 103 
making it a promising target for therapeutic vectors. αvβ6 is an activator of TGF-β1 signalling 104 
that promotes metastasis by enhancing angiogenesis, immune cell suppression and 105 
epithelial-to-mesenchymal transition [reviewed in (10)].  106 
Cancer virotherapy is undergoing renewed interest, including recent regulatory 107 
approval for clinical use of herpes simplex type 1-based talimogene laherparepvec (T-VEC), 108 
the first oncolytic immunotherapy approved for advanced melanoma (11). Very recently 109 
oncolytic viruses were shown to sensitise difficult-to-treat tumours, including triple-negative 110 
breast cancer (TNBC) (12) and glioblastoma (13) to subsequent immunotherapies with 111 
immune checkpoint inhibitors. This highlights the potential of virotherapies for combination 112 
studies in the clinical setting, and the scope for generating a vector capable of systemically 113 
targeting tumours following intravenous introduction. Adenovirus serotype 5 (Ad5) has been 114 
commonly deployed in clinical trials of cancer and gene therapies (14), due to ease of 115 
genetic manipulation and capacity for large transgenes (15). However, this serotype has 116 
sub-optimal features that hamper its wider clinical use. As a common respiratory virus with 117 
high seroprevalence rates (16), efficient neutralisation of vector by neutralising antibodies 118 
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(nAbs) limits efficacy. Other limitations include significant and rapid off-target sequestration 119 
to spleen and liver via complexing of the virion with human coagulation factor 10 (FX) (17) 120 
and potentially other coagulation factors [reviewed extensively in (18)], “bridging” the 121 
complex to heparan sulphate proteoglycans (HSPGs), abundant on hepatocytes (19). In 122 
vitro, Ad5 enters host cells via coxsackie and adenovirus receptor (CAR) (20) that is 123 
ubiquitous within tight junctions on polarised epithelial cells [reviewed in (21)] but commonly 124 
down-regulated in progressive cancers (22-26), limiting use of wild-type Ad5 for tumour 125 
therapy.  126 
We have generated a novel virotherapy vector, Ad5NULL-A20, with altered, tumour-127 
selective tropism. We ablated all native tropisms of Ad5 by mutating key residues in the 128 
three main capsid proteins (hexon, fiber and penton) and re-targeted the resulting vector, 129 
Ad5NULL, to the tumour-selective integrin αvβ6 through incorporation of an αvβ6-binding 130 
peptide (A20, NAVPNLRGDLQVLAQKVART) within the fiber knob domain HI loop, 131 
generating the novel vector Ad5NULL-A20. A20 peptide was originally derived from foot-and-132 
mouth disease virus (FMDV) capsid protein VP1, and has high affinity for its native receptor, 133 
αvβ6 integrin (27, 28). We have investigated potential clinical utility of an oncolytic variant of 134 
Ad5NULL-A20 (24/T1) for intra-peritoneal treatment of ovarian cancer by investigating its bio-135 
distribution, tumour-selective oncolytic capabilities and avoidance of immune neutralisation 136 
using in vitro and in vivo models of human EOC. 137 
MATERIALS AND METHODS 138 
Adenovirus vectors, cell lines and clinical ascites 139 
All vectors generated in this study included a luciferase (Luc) reporter gene. Genetic 140 
modifications were carried out by AdZ homologous recombineering methods (29) as 141 
described previously (30). Viruses were produced in T-REx-293 or HEK293-β6 cells (for 142 
A20-modified viruses) and purified as described previously (30, 31). A triply de-targeted 143 
vector genome, Ad5NULL, was generated by introducing mutations in key genes encoding of 144 
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each of the major capsid proteins to preclude cellular uptake by all known native Ad5 145 
pathways.  Ablation of binding to CAR was achieved via the KO1 mutation in the AB loop of 146 
the L5 fiber knob gene; ablation of binding to coagulation factor 10 (FX) via a mutation in 147 
hypervariable region 7 of the L3 hexon gene; and ablation of αvβ3/5 integrin binding via 148 
RGD-to-RGE mutation in the L2 penton base gene. αvβ6 re-targeting was achieved by 149 
insertion of sequences encoding peptide A20 (NAVPNLRGDLQVLAQKVART) into the fiber 150 
knob HI loop (between residues G546 and D547) of Ad5NULL, generating Ad5NULL-A20. 151 
Replication-deficient variants of Ad5NULL-A20 carry a complete E1/E3 deletion. Oncolytic 152 
variants have a 24-base pair deletion (dl922‒947) in the retinoblastoma protein (pRB) 153 
binding domain of E1A (Δ24) (32) and a single adenine insertion at position 445 within the 154 
endoplasmic reticulum (ER) retention domain of E3/19K [T1 mutation; (33)]. Additional 155 
details of genetic modifications are provided in Supplementary Methods. 156 
Homology modelling was performed using the previously published Ad5 fiber knob structure 157 
[PDB ID: 1KNB (34)] and foot-and-mouth disease virus O PanAsia VP1 protein in complex 158 
with ανβ6 [PDB ID: 5NEM (35)]. The peptide sequence forming the interaction with ανβ6 159 
(NVRGDLQVLAQKVART) was edited to conform with the A20 peptide sequence used in this 160 
study (NAVPNLRGDLQVLAQKVART), docked to the Ad5 fiber knob structure in the HI loop 161 
and the KO1 mutation added using WinCoot (36) and PyMol 2.0 (37). The crude Ad5NULL-162 
A20 structure was aligned with the existing 5NEM structure and the complex energy 163 
minimised using the YASARA algorithm (38). Binding energy calculations were performed 164 
using PISA (39), and surface charge calculated using APBS tool in PyMol 2.0 (37). 165 
αvβ6-high/CAR+ SKOV3-β6 cell line was generated in-house by retroviral transfection 166 
of SKOV3 cells [that natively express the αv subunit (40)] with integrin beta6 pBABE puro 167 
plasmid to express the 6 subunit. Primary EOC cells from ascites were obtained through 168 
Wales Cancer Bank under existing ethical permissions (WCB 14/004). Cells were processed 169 
and sub-cultured as described previously (30, 31), and tested regularly for Mycoplasma 170 
infection by commercially available PCR-based methods. 171 
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In vitro and in vivo studies 172 
Cell surface receptor expression was assessed by flow cytometry (30). The presence 173 
of anti Ad5 antibodies in ovarian ascites and serum was determined by ELISA as previously 174 
reported (41). Antigen specificity of the antibodies was assessed by Western blot. 175 
Transduction efficiency was assessed by standard luciferase assays, described previously 176 
(30, 31). Animal experiments were approved by Institutional Care and Use Committee 177 
(IACUC) and performed at Mayo Clinic, Rochester, MN, USA. Animals were age and sex-178 
matched. Animal handling and injections were performed by a veterinary technologist. In 179 
vivo experiments are further described in detail in Supplementary Methods.  180 
Statistical analyses 181 
Figures and statistical analyses were generated using GraphPad Prism v6.03. In vitro 182 
and ex vivo assays were analysed by two-tailed unpaired t-tests or one-way ANOVA with 183 
Dunnett’s multiple comparisons post hoc test. In vivo data was normalised and analysed by 184 
one-way ANOVA or Kruskal–Wallis test with Sidak’s or Dunn’s multiple comparisons post 185 
hoc test, respectively. Overall survival (%) following oncolytic treatment is shown as a 186 
Kaplan‒Meier survival curve; survival proportions were analysed by Gehan‒Breslow‒187 
Wilcoxon test. 188 
RESULTS 189 
We generated and produced to very high viral titres replication-defective and oncolytic 190 
variants of a novel Ad5NULL-A20 vector (Fig. 1A) with three de-targeting mutations and an 191 
A20 peptide insertion that re-targets the vector to αvβ6 integrin-expressing cells (Fig. 1B). 192 
Additionally, we generated replication deficient and oncolytic versions of Ad5.A20, which 193 
harbours the αvβ6 targeting-peptide A20 insertion, in the absence of any de-targeting 194 
modification. The multiple genetic manipulations did not have a significant impact on viral 195 
titre (Fig. 1A).  196 
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We generated a homology model of the Ad5NULL-A20 fiber knob protein in complex with the 197 
ανβ6 dimer (Fig. 1C). The A20 peptide (dark blue) occupies space spanning both αν (green) 198 
and β6 (purple) subunits. The predicted Ad5NULL-A20 interacting residues of the A20 peptide 199 
(dark blue) and the native knob structure (cyan) against the approximated charge surface of 200 
the ανβ6 (red is negative, blue is positive, Fig. 1D). The ανβ6 has mostly negative surface 201 
potential in this region (1D), complementary to the predominantly positive charge of the 202 
Ad5NULL-A20 interface (Suppl. Fig. I A). The adjacent CD loop of the native Ad5 fiber knob 203 
contributes two polar residue interactions from Lys-442 and Gly-443 (1D), binding to an 204 
additional three αν residues (Suppl. Fig. I B). The binding energy of the ανβ6-Ad5NULL-A20 205 
fiber knob complex is calculated to be –24.3 Kcalmol-1, suggesting an exceptionally stable 206 
interface (Suppl. Fig. I C), providing confidence that our αvβ6 targeting strategy was 207 
feasible. 208 
The transduction efficiency of replication-deficient vectors was assessed in cell lines 209 
expressing variable levels of CAR and αvβ6 integrin. The de-targeting mutation triplet of 210 
Ad5NULL-A20 completely abolished entry via CAR in CHO-CAR cells (CAR+), while Ad5 211 
transduced these cells at expectedly high efficiency (Fig. 2A). The HVR7 mutation abolished 212 
Ad5 vector transduction via FX pathway (Fig. 2B) (42). As expected, FX significantly 213 
increased transduction of Ad5 into CHO-K1 cells as compared to FX-free culture conditions 214 
(Fig. 2B; left panel). Conversely, addition of human FX in culture medium had no effect on 215 
the transduction efficiency of the FX binding-ablated Ad5.HVR7 control vector in these cells 216 
(Fig. 2B; right panel). Furthermore, the enhanced transduction seen for Ad5 was reversed by 217 
the addition of a 3:1 molar excess of Gla-domain interacting protein, anticoagulant X-bp, that 218 
binds and inactivates FX in the medium (19) (Fig. 2B, left panel). On the contrary, FX 219 
depletion did not affect the transduction of Ad5.HVR7 vector (Fig. 2B, right panel).   220 
We confirmed αvβ6 integrin as the primary entry receptor for the triply de-targeted, 221 
integrin re-targeted Ad5NULL-A20 vector (Fig. 3). Ad5NULL-A20 transduced αvβ6+/CAR‒ BT-20 222 
breast cancer cells with 305-fold higher efficiency (Fig. 3A; p=0.0270) and primary, patient 223 
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derived EOC004 cells (αvβ6+/CAR‒) at 69-fold increased efficiency (Fig. 3B; p=0.0090) 224 
relative to Ad5. Competition assays using a function-blocking anti-αvβ6 antibody (10D5) 225 
significantly inhibited cell transduction by Ad5NULL-A20 vector in SKOV3-β6 cells 226 
(αvβ6+/CAR+) (Fig. 3C; p=0.0010), confirming the vector’s selectivity for αvβ6 integrin 227 
We next evaluated the ability of the Ad5NULL-A20 vector to retain its infectivity in the 228 
highly neutralising environment presented by ovarian ascites. To this end, freshly isolated 229 
clinical OAS samples from twenty ovarian cancer patients were screened for the presence of 230 
anti-Ad5 antibodies by direct ELISA. The titres of anti-Ad5 abs in malignant ovarian ascites 231 
were scrutinised against the serum anti-Ad5 antibody titre of a healthy adult male volunteer 232 
(Fig. 4A). Equal proportion of patients were found to have lower and higher antibody titres 233 
than the control serum (Fig. 4A, black dashed line). Ascites from patient 001 (OAS001) was 234 
chosen for subsequent neutralisation assays due to its similar antibody titre with the control 235 
serum. Antibodies in OAS001 and control serum appeared specific for the viral fiber protein, 236 
whilst the most abundant capsid protein – hexon – was recognised only at very low levels in 237 
Western blot using denatured whole viral particles (Fig. 4B). The neutralising effect of 238 
OAS001 on transduction efficiency of Ad5NULL-A20 was assessed in αvβ6+/CAR– EOC004 239 
primary cells. Ad5NULL-A20 showed up to 902-fold higher transduction efficiency in primary 240 
human EOC cultures relative to Ad5 at OAS concentrations of 2.5, 5 and 10%, whilst Ad5 241 
was not capable of transducing these cells at detectable levels (Fig. 4C).  242 
We next evaluated biodistribution of virus infection in immunocompetent, non-tumour-243 
bearing mice. Mice were injected intravenously with replication-defective vectors to assess in 244 
vivo tropism (Fig. 5A), in particular the effect of the three de-targeting mutations on 245 
biodistribution of virus infection. As expected and as previously documented, the Ad5 vector 246 
showed intense localisation in the area of liver and spleen, while luminescence by the 247 
Ad5NULL-A20 vector was completely undetectable at the 72-h time-point (Fig. 5B). Animals 248 
inoculated with Ad5 vector had significantly higher whole-body luminescence than the 249 
control animals (p<0.0001) or the Ad5NULL-A20 vector (p<0.0001) (Fig. 5C). The liver, spleen, 250 
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lungs, ovaries and heart were resected post-mortem and quantified for ex vivo luminescence 251 
(for luminescence heat-maps, see Suppl. Fig. II A‒C). The livers of Ad5-challenged animals 252 
emitted significantly more luminescence than the PBS control or Ad5NULL-A20 groups (both 253 
p<0.0001) (Fig. 5D). Similarly, Ad5NULL-A20 had significantly decreased transgene 254 
expression in the spleen, lungs, ovaries and heart, relative to Ad5 (Fig. 5E‒H; p<0.0001 for 255 
all). For fold changes in luminescence intensity in each off-target organ, see Suppl. Fig. II D.  256 
Confirmation that the modifications in Ad5NULL-A20 resulted in reduced sequestration of 257 
virus in multiple normal tissues was performed via quantitation of viral load by qPCR. 258 
Genome copy number of the Ad5NULL-A20 vector was 10 million times lower in the liver 259 
relative to the Ad5 (Fig. 6A; p<0.0001). Similarly, Ad5NULL-A20 genome copy number was 260 
over 700-fold lower in the spleen compared to Ad5 (Fig. 6B; p<0.0001). In addition, the 261 
Ad5NULL-A20 vector showed improved off-target profiles in all organs relative to Ad5, with 262 
viral load 105, 104 and 103 lower in the lungs, heart and ovaries, respectively (Fig. 6C‒E). 263 
Successful de-targeting of the liver being due to our genetic modifications of Ad5 is 264 
supported by immunohistochemical staining of liver sections, which showed high expression 265 
levels of CAR, whilst αvβ6 was undetectable (Suppl. Fig. III A). Confirmation of the de-266 
targeting effects of genetic modifications in Ad5NULL-A20 is provided by the observation that 267 
liver sections from mice showed positive staining for Ad capsid proteins in the Ad5 group, 268 
but not in livers of mice that had been challenged with the Ad5NULL-A20 vector (Suppl. Fig. III 269 
B).  270 
To evaluate efficacy in a human EOC model in vivo, SKOV3 human ovarian cancer 271 
xenografts were established in immuno-compromised NOD/SCID mice. Animals developed 272 
large solid tumours at the cell injection site and at various sites within the peritoneal cavity 273 
within 14 days after intra-peritoneal implantation of SKOV3 cells (for tumour localisation and 274 
take rate, see Suppl. Fig. IV) and by day 49, tumours were spread throughout the peritoneal 275 
cavity with accumulation of large volumes of ascites. Based on these observations, we 276 
performed virotherapy efficacy studies by delivering three intraperitoneal doses of oncolytic 277 
12 
 
variants of Ad5, Ad5.A20 and Ad5NULL-A20 vectors on days 14, 16 and 18 post-implantation 278 
of SKOV3 cells. 279 
IVIS imaging at 48 h after first virotherapy treatment dose (day 16) showed widespread 280 
luminescence throughout the abdominal region in animals with SKOV3 xenografts and 281 
treated with the oncolytic Ad5 vector, with highest intensity in the liver/spleen region (Fig. 282 
7B). This distribution was maintained, but at lower intensity, until 5 days later, day 21 (Fig. 283 
7B).  In contrast, the oncolytic Ad5NULL-A20 vector however, showed selective tumour 284 
localisation, with significantly reduced overall luminescence relative to Ad5, consistent with 285 
successful de-targeting of non-tumour tissues. The distribution of infection mediated by the 286 
oncolytic Ad5.A20 vector was intermediate between the Ad5 and Ad5NULL-A20. Quantitation 287 
of total body luminescence showed uptake of the Ad5NULL-A20 vector to be significantly lower 288 
than Ad5 both on day 16 (Fig 7C; p<0.05 and <0.01, respectively) and on day 21 (Fig. 7D; 289 
p<0.0001), while there was no statistically significant difference in the uptake of Ad5.A20 as 290 
compared to Ad5.  291 
Anti-tumour activity was observed for oncolytic Ad5, oncolytic Ad5.A20 and oncolytic 292 
Ad5NULL-A20 in the SKOV3 xenograft model (Fig 7E). Consistent with an enhanced tumour-293 
selective effect of Ad5NULL-A20, all mice treated with Ad5NULL-A20 were still alive and tumour-294 
free at the final time-point of 101 days, while animals treated with either Ad5 or Ad5.A20 295 
almost identical (and statistically not significantly different) survival curves with median 296 
survival of around 60 days. 297 
  298 
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DISCUSSION 299 
We describe here an exquisitely refined and tumour-selective oncolytic adenoviral 300 
vector, Ad5NULL-A20 which is ablated for all known native tropisms and re-targeted to an 301 
over-expressed, prognostic cancer marker ‒ αvβ6 integrin (43). Integrin αvβ6 is a promising 302 
target for therapeutic cancer applications due to its over-expression in aggressively 303 
transformed cancers (4). A20 peptide is a feasible tool for a variety of clinical applications, 304 
and has been used for imaging diagnostics in an αvβ6+ pancreatic tumour model (44) and in 305 
a humanised single-chain Fv antibody B6-2 (45). αvβ6 is emerging as a promising target for 306 
a range of advances therapies including those based on chimaeric antigen receptor (CAR) 307 
T-cell immunotherapies [reviewed in (46)], where efficacy in the αvβ6 expressing SKOV3 cell 308 
lines has been demonstrated. Furthermore, the αvβ6-blocking antibody, 264RAD showed 309 
promising in vivo efficacy in HER2+/αvβ6+ breast cancers in combination with monoclonal 310 
antibody trastuzumab (47), and is being developed for phase I clinical trials. αvβ6 therefore 311 
represents a highly appealing target for cancer treatment across a range of technologies and 312 
therapeutic applications. 313 
In silico evaluation of the Ad5NULL-A20 interface with ανβ6 by homology modelling (Fig. 314 
1; Suppl. Fig. I) predicts the Ad5NULL-A20 fiber knob domain to form a low entropy interface 315 
with ανβ6. A20 possesses the putative RGD integrin interacting motif (48) but specificity to 316 
the β6 subunit is derived from the helical motif C-terminal of RGD. It is further stabilised by 317 
electrostatic interactions across the interface and polar bonds between αν and the Ad5 CD 318 
loop. Each fiber trimer possesses three copies of the A20 peptide, with 12 trimeric fibers per 319 
adenovirus capsid, thus Ad5NULL-A20 possesses 36 potential ανβ6 interaction sites per viral 320 
particle. While not all these sites will be utilised in a single cellular interaction it is extremely 321 
likely that the virus benefits from a potent avidity effect when interacting with a cell 322 
possessing multiple ανβ6 copies. 323 
In the present study, we presented the Ad5NULL-A20 as a highly selective vector 324 
platform. A replication-defective form of Ad5NULL-A20 vector successfully de-targeted viral 325 
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uptake by cells via native viral uptake pathways (Fig. 2), instead selectively re-targeting 326 
αvβ6+ cells, in vitro and ex vivo (Fig. 3). Although the efficacy-limiting interactions that occur 327 
in systemic delivery of adenoviral vectors can, theoretically, be bypassed by intra-cavity 328 
administration of the vector via the i.p. route, in practice this approach presents challenges 329 
since wild-type Ad5 is sequestered by pre-existing anti-Ad5 immunity in the form of 330 
neutralising antibodies (nAbs) in ascitic fluid (41, 49, 50). We therefore assessed the 331 
transduction efficiency of Ad5NULL-A20 in the presence of freshly-isolated clinical OAS from 332 
ovarian cancer patients with confirmed high levels of anti-Ad5 nAbs (Fig. 4A). Unlike the Ad5 333 
vector, Ad5NULL-A20 retained its ability to transduce αvβ6+ cells, even at relatively high OAS 334 
concentrations (Fig. 4C).  335 
Clinical efficacy of therapeutic Ad5 vectors with unmodified capsids is also significantly 336 
limited by off-target tissue sequestration, particularly in the liver. We demonstrate that 337 
Ad5NULL-A20 significantly altered the biodistribution of the Ad5 vector in vivo by reducing the 338 
sequestration in remarkable magnitudes. In tumour-free mice, replication-deficient Ad5NULL-339 
A20 demonstrated significantly reduced viral transgene expression the liver, spleen and 340 
lungs compared to the parental Ad5 (Fig. 5), and lower viral genome copy number in all off-341 
target organs relative to the Ad5 vector (Fig. 6).  342 
To test efficacy of an oncolytic form of our de-targeted/re-targeted Ad5NULL-A20 vector, 343 
we established an orthotopic i.p. xenograft model of human EOC SKOV3 in 344 
immunocompromised mice. The more localised bio-distribution of virally-encoded transgene 345 
expression of oncolytic Ad5NULL-A20 following intraperitoneal administration was consistent 346 
with reduced off-target sequestration and/or tumour-selective virus uptake (Fig. 7B–E). This 347 
was supported by the superior survival of animals treated with Ad5NULL-A20 relative to Ad5 in 348 
a SKOV3 xenograft model (Fig. 7E), although extended survival (compared to unmodified 349 
Ad5) was not observed in mice treated with the oncolytic Ad5.A20 variant. This observation 350 
highlights that efficacy in vivo depends upon both the combination of complete ablation of all 351 
native means of cellular uptake via hCAR, αvβ3/5 integrins and FX, coupled with an efficient 352 
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and selective retargeting mechanism to tumour-associated ligands, such as the αvβ6: A20 353 
receptor: ligand interaction. This observation likely explains previous studies (51, 52) which 354 
described no improved efficacy (compared to oncolytic Ad5) of virotherapies targeted to 355 
αvβ6 integrin, since the vectors used in those studies lacked modifications in at least two of 356 
the three native infectious pathways (the hexon: FX and penton base: αvβ3/5 interactions). 357 
Additional studies will be needed to fully evaluate v6+ cancer re-targeting in vivo, as well 358 
as to dissect the fate in tissues and immunological responses to the Ad5NULL-A20 vector.  359 
Local, i.p. Ad5NULL-A20 administration presents a promising treatment option for 360 
advanced, chemotherapy-resistant, αvβ6+ ovarian cancer. Here, we describe a novel vector 361 
that can be further manipulated for various clinical applications, with the scope of selective 362 
targeting to αvβ6 integrin-expressing cells and minimal off-target effects that limit current 363 
Ad5-based therapies. Ad5NULL-A20 vector provides an agile and versatile platform that could 364 
ultimately be modified for precision virotherapy applications by various innovative 365 
approaches, potentially providing a platform for the local, tumour selective over-expression 366 
of additional, virally encoding therapeutic modalities, such as immunotherapies. 367 
  368 
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FIGURE LEGENDS 383 
Figure 1. Generated vectors. (A) Viral titres and expected tropisms of Ad5 and triply de-targeted, 384 
αvβ6 integrin re-targeted vector, Ad5NULL-A20; (B) Vector map of the oncolytic Ad5NULL-A20; (C) 385 
Homology modelling of the adenovirus serotype 5 fiber knob with A20 peptide 386 
(NAVPNLRGDLQVLAQKVART; dark blue) within the HI loop of fiber knob domain (Ad5.A20; in light 387 
blue) in complex with αν (green) and β6 (magenta) integrin subunits shows a potential mechanism for 388 
the Ad5NULL-A20 interface. (D) Residues in both αν and β6 subunits form hydrogen bonds (red 389 
dashes), stabilising a charged interface (ανβ6, negative; A20, positive). Residues in Ad5s CD loop 390 
form further polar interactions. CAR, coxsackie and adenovirus receptor; FX, coagulation factor 10; 391 
HVR7, hypervariable region 7 (42); KO1, CAR-binding mutation in fiber knob AB loop (53); Luc, 392 
luciferase transgene; repl. def., replication-defective; vp, viral particle.  393 
Figure 2. Ablation of native receptor tropisms. (A) Binding of replication-deficient Ad5 and 394 
Ad5NULL-A20 vectors to coxsackie and adenovirus receptor (CAR). Ratio of viral transgene expression 395 
from Ad5NULL-A20 relative to Ad5 is indicated above bars. (B) Binding of replication-deficient Ad5 and 396 
HVR7-mutated Ad5 variant (42) to coagulation factor 10 (FX) was assessed in luciferase assays by 397 
infecting CHO-K1 cells in the presence of human FX with (+) or without (–) anticoagulant X-bp. HVR7, 398 
FX-binding mutation. Statistical significance: ns, p>0.05; **, p<0.01. 399 
Figure 3. In vitro assessment of αvβ6 integrin re-targeting. Transduction efficiency of replication-400 
deficient wild-type (Ad5) and triply-detargeted, integrin re-targeted (Ad5NULL-A20) vectors in (A) αvβ6+ 401 
BT-20 breast cancer cells and (B) αvβ6+ primary epithelial ovarian cancer (EOC) cells from patient 402 
004. (C) Competition inhibition of αvβ6 integrin-mediated cell entry in SKOV3-β6 cells. The highest 403 
10% αvβ6-expressing SKOV3-β6 cells were sorted by FACS, sub-cultured and infected. IgG, normal 404 
mouse IgG control; 10D5, anti-αvβ6 function-blocking antibody. Ratio of viral transgene expression is 405 
indicated above bars.  Statistical significance: ns, p>0.05; *, p<0.05; **, p<0.01; ***, p<0.001; ****, 406 
p<0.0001. 407 
Figure 4. The effect of malignant ovarian ascites on vector transduction ex vivo. (A) 408 
Quantification of anti-Ad5 antibodies in twenty clinical ovarian ascites (OAS) samples and control 409 
serum from a healthy male volunteer (solid black line) by ELISA. Horizontal lines indicate 50% and 410 
100% binding of anti-Ad5 abs in the control serum. (B) Antigen specificity of anti-Ad5 antibodies in 411 
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ascites and serum by Western blot, using denatured whole virus particles. (C) Vector transduction 412 
efficiency of replication-defective (Ad5) and Ad5NULL-A20 vectors, in the absence and presence of 413 
varying dilutions of ascites from an ovarian cancer patient 004 in primary ex vivo culture of epithelial 414 
ovarian cancer cells from patient 004. Cells were pre-incubated with ascending concentrations of 415 
ascites and infected. 416 
Figure 5. Biodistribution of replication-defective vector infection at 72 h following systemic 417 
delivery in non-tumour-bearing animals. (A) Biodistribution study schedule and (B) in vivo imaging 418 
of biodistribution of replication-defective (Ad5) and triply de-targeted Ad5NULL-A20 virus, 3 days after 419 
intravenous injection in the tail vein. Quantitation of total luminescence signal from panel B:  in (C) 420 
whole body, (D) liver, (E) spleen, (F) lungs, (G) ovaries and (H) heart. i.p., intraperitoneal; IVIS, in vivo 421 
imaging system; p.i., post-infection; vp, viral particle. Error bars represent standard error of the mean; 422 
n=5/group; ns, p>0.05; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 423 
Figure 6. Viral genome copy number in off-target organs at 72 hours following systemic 424 
delivery. Adenovirus genome copy number from tissues excised from animals in Fig. 5: (A) liver, (B) 425 
spleen, (C) lungs, (D) ovaries and (E) heart, as determined by qPCR for the hexon gene, following 426 
systemic vector delivery. Error bars represent standard error of the mean; n=5/group; ns, p>0.05; *, 427 
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. Numbers below graphs indicate fold decrease of the 428 
Ad5NULL-A20 group relative to the Ad5 group. 429 
Figure 7. Oncolytic efficacy study: intraperitoneal delivery of oncolytic vectors in ovarian 430 
cancer xenograft model. (A) Study schedule. Intraperitoneal xenografts of human ovarian cancer 431 
SKOV3 cells were implanted into immune-compromised mice (n=5/group), then animals were treated 432 
with 3 doses of intravenous oncolytic Ad5, αvβ6 integrin re-targeted Ad5.A20 or triply de-targeted, 433 
αvβ6 integrin re-targeted Ad5NULL-A20, on days 14, 16 and 18. (B) Luminescence heat map images 434 
and quantitation of total body luminescence were determined at 48 h after the first treatment (C; Day 435 
16), and at 7 days after the first treatment (D; Day 21). (E) Overall survival of animals inoculated with 436 
SKOV3 xenografts (αvβ6-low/CAR+) and then treated with virus, as above, shown as a Kaplan‒437 
Meyer survival curve until the final study endpoint of 101 days. i.p., intraperitoneal; IVIS, in vivo 438 
imaging system; vp, viral particle *, p<0.05; **, p<0.01; ***, p<0.001. IVIS, In Vivo Imaging System. 439 
  440 
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